According to CNBC, TD Cowen upgraded UnitedHealth to buy from hold and raised its price target to $455 from $402, implying 38% upside from Thursday's close. Shares fell 14% over the past three months. Analyst Ryan Langston said UnitedHealth has a credible path to mid- to high-teens EPS growth through at least 2028, supported by Medicare Advantage benefit design, an Optum Health recovery and improvement in Commercial and Medicare-Medicaid Dual Complete. Earlier this month, the Centers for Medicare & Medicaid Services proposed an anti-fraud rule for Medicare and Medicare Advantage, raising concerns about increased scrutiny of UnitedHealth's Medicare Advantage business. Langston said the uncertainty would not derail progress at Optum Health and expected another year of solid margin expansion there in '27. He also identified continued external growth at Optum Rx and commercialization of Optum Insight's AI-first products as areas to watch. Of 28 analysts covering UnitedHealth, 25 rate the stock buy or strong buy, according to LSEG data.
